Bliss GVS Pharma Ltd.
| BSE: 506197 | Sector: Health care |
| NSE: BLISSGVS | ISIN Code: INE416D01022 |
| BSE 00:00 | 20 May | 72.20 |
0.75 (1.05%) |
OPEN
73.00 |
HIGH
74.10 |
LOW
71.40 |
| NSE 00:00 | 20 May | 72.15 |
0.80 (1.12%) |
OPEN
72.00 |
HIGH
74.00 |
LOW
71.55 |
| OPEN | 73.00 |
| PREVIOUS CLOSE | 71.45 |
| VOLUME | 18926 |
| 52-Week high | 128.40 |
| 52-Week low | 66.25 |
| P/E | 8.26 |
| Mkt Cap.(Rs cr) | 749 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Bliss GVS Pharma Ltd. (BLISSGVS) - Latest News & Headlines
-
Bliss GVS Pharma Ltd Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (LODR) Regulations 2015
14/05/2022 | bse |
Downlaod PDF -
Bliss GVS Pharma Ltd Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
13/05/2022 | bse |
Downlaod PDF -
Bliss GVS Pharma Ltd Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
09/05/2022 | bse |
Downlaod PDF -
Bliss GVS Pharma Ltd Announcement under Regulation 30 (LODR)-Newspaper Publication
02/05/2022 | bse |
Downlaod PDF -
Bliss GVS Pharma Ltd Intimation Of Book Closure For 37Th Annual General Meeting & Payment Of Final Dividend For The Finan
30/04/2022 | bse |
Downlaod PDF
-
Ruchi Soya acquires Patanjali Ayurved's food business for Rs 690 crore
1.32 am | 19 May 2022 | Business Standard
To pay 1% of turnover of products as annual royalty under transfer agreement
-
Ruchi Soya hits upper circuit on buyout of Patanjali's food retail business
3.58 pm | 18 May 2022 | Business Standard
The board also approved to change company's name from Ruchi Soya Industries to Patanjali Foods.
-
Gokaldas Exports surges 9%; hits all-time high on healthy business outlook
10.17 am | 18 May 2022 | Business Standard
A shift in consumer preferences post pandemic towards wovens, as people seek more formal clothes, may improve demand.
-
UltraTech, JSW lost Ambuja race due to CCI concerns: Holcim CEO
1.44 am | 18 May 2022 | Business Standard
The CEO said the smoothness of the execution of such a transaction was a major factor in taking the decision.
-
Street betting on revival of metals cycle amid buzz of over-correction
11.42 pm | 17 May 2022 | Business Standard
High input costs leading to margin pressure, lower-than-expected realisations are among downside risks
Quick Links for Bliss GVS Pharma:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
